Next-Generation T-Cell Engagers: Leveraging Protease Activation to Overcome Toxicity & Expand the Therapeutic Window
4:30 pm - Wednesday 9th December 2026
- The efficacy of T-cell engagers in solid tumors is often limited by systemic toxicities, including on-target/off-tumor effects
- Our next-generation approach utilizes a conditionally-activated platform designed to restrict T-cell engagement to the tumor microenvironment via tumor-associated proteases
- This strategy minimises off-tumor activity and systemic immune activation while maintaining robust anti-tumor efficacy, thereby significantly widening the therapeutic window for treatment
